Expression of cell cycle inhibitor p27 and Ki-67 in human adrenocortical neoplasms

Modern Pathology

Volumn 11, Issue 12, 1998, Pages 1165-1170

  Nakazumi, Hisayoshi ^a   Sasano, Hironobu ^a   Iino, Kazumi ^a   Ohashi, Yusuke ^a   Orikasa, Seiichi ^a  

^a TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Adrenal cortex; Cell proliferation; Immunohistochemistry; Ki 67; P27

Indexed keywords

CELL CYCLE PROTEIN; INHIBITOR PROTEIN; KI 67 ANTIGEN; PROTEIN P27;

ADRENAL CORTEX ADENOMA; ADRENAL CORTEX CARCINOMA; ADRENAL CORTEX TUMOR; ADULT; AGED; ARTICLE; CELL CYCLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LABELING INDEX; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADENOMA; ADRENAL CORTEX; ADRENAL CORTEX NEOPLASMS; ADULT; AGED; CARCINOMA; CELL COUNT; CUSHING SYNDROME; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; KI-67 ANTIGEN; MALE; MICROFILAMENT PROTEINS; MIDDLE AGED; MUSCLE PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 0032427744     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Iino K, Sasano H, Yabuki N, Oki Y, Kikuchi A, Yoshimi T, et al. DNA topoisomerase 11 α and Ki-67 in human adrenocortical neoplasms: a possible marker of differentiation between adenomas and carcinomas. Mod Pathol 1997;10:901-7.
2. Goldblum JR, Shannon R, Kaldjian EP, Thiny M, Davenport R, Thompson N, et al. Immunohistochemical assessment of proliferative activity in adrenocortical neoplasms. Mod Pathol 1993;6:663-8.
3. Suzuki T, Sasano H, Nisikawa T, Rhame J, Wilkinson DS, Nagura H. Discerning malignancy in human adrenocortical neoplasms: utility of DNA flow cytometry and immunohistochemistry. Mod Pathol 1992;5:224-30.
4. Sasano H, Imatani A, Shizawa S, Suzuki T, Nagura H. Cell proliferation and apoptosis in normal and pathologic human adrenal. Mod Pathol 1995;8:11-7.
5. Kip1 and Ki-67 in benign and malignant thyroid tumors. Mod Pathol 1998;11:169-174.
6. Hunter T, Pines J. Cyclins and cancer II: cyclin D and inhibitors come of age. Cell 1994;79:573-82.
7. King RW, Jackson PK, Kirschner MW. Mitosis in transition. Cell 1994;79:563-71.
8. Sasano H, Frost AR, Saitoh R, Taniyama Y, Nagura U, Matsunaga G, et al. Immunolocalization of cyclins D and E and cyclin-dependent kinase (cdk) 2 and 4 in human breast carcinoma. Anticancer Res 1997;17:3685-90.
9. Vincenzo E, Alfonso B, Antonio DL, Angela MG, Massimo L, Giovan GG, et al. Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res 1997;57:3381-5.
10. Sherr CJ. Mammalian G1 cyclins. Cell 1993;73:1059-65.
11. Loda M, Cukor B, Tam SW, Lavin P, Fiorentino M, Draetta G, et al. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor, p27, in aggressive colorectal carcinomas. Nat Med 1997; 3:152-4.
12. Tan P, Cady B, Wanner M, Worland P, Cukor B, Magi-Galluzzi P, et al. The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a, b) invasive breast carcinomas. Cancer Res 1997;57:1259-63.
13. Kip1 cyclin-dependent kinase inhibitor prevented by rapamycin. Nature 1994;372:570-3.
14. Kip1 for restriction point control of the fibroblast cell cycle. Science 1996;272:877-80.
15. Pagano M, Tam SW, Theodoras AM, Romero-Beer P, Del Sal G, Chau V, et al. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor, p27. Science 1995;269:682-5.
16. Kip1, in human malignancies. Cancer Res 1995;55:2266-9.
17. Kip1 mutation found in breast cancer. Cancer Res 1996;56:2400-4.
18. Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med 1997;3:222-5.
19. Kip1 protein: prognostic implications in primary breast cancer. Nat Med 1997;3:227-30.
20. Reinke M, Nieke J, Krestin GP, Saeger W, Allolio B, Winkelmann W. Preclinical Cushing's syndrome in adrenal "incidentalomas": comparison with adrenal Cushing's syndrome. J Clin Endocrinol Metab 1992;75:826-32.
21. Newell-Price J, Grossman A. Adrenal incidentaloma: subclinical Cushing's syndrome. Postgrad Med J 1996;72:207-10.
22. Kip1, is associated with advanced stage and invasiveness of gastric carcinomas. Jpn J Cancer Res 1997;88:625-9.
23. Kip1-deficient mice. Cell 1996;85:733-44.
24. Kip1. Cell 1996;85:721-32.
25. Qian X, Jin L, Grande JP, Lloyd RV. Transforming growth factor-β and p27 expression in pituitary cells. Endocrinology 1996;137:3051-60.
26. Kip1 expression in endocrine and other tumors. Am J Pathol 1997;150:401-7.
27. Nakano M. Adrenal cortical carcinoma: a clinicopathological and immunohistochemical study of 91 autopsy cases. Acta Pathol Jpn 1988;38:163-80.
28. Hough AJ, Hollifield JW, Page DL, Hartmann WH. Prognostic factors in adrenal cortical tumors. Am J Clin Pathol 1979;72: 390-8.
29. Weiss LM. Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors. Am J Surg Pathol 1984;8:163-9.